Many biotech stocks took a beating as the likes of Valeant, Mylan, and Turing became a political issue during last year's presidential campaign. We enter 2017 with many companies priced so attractively that they have become acquisition targets. Todd Hagopian outlines his top takeover targets.
Many biotech stocks took a beating as the likes of Valeant, Mylan, and Turing became a political issue during last year's presidential campaign. We enter 2017 with many companies priced so attractively that they have become acquisition targets. Todd Hagopian outlines his top takeover targets.
Share this Article
Recommended